DaVita Inc. (DVA)
| Market Cap | 9.90B |
| Revenue (ttm) | 13.64B |
| Net Income (ttm) | 746.80M |
| Shares Out | 65.94M |
| EPS (ttm) | 9.84 |
| PE Ratio | 15.78 |
| Forward PE | 10.63 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 466,374 |
| Open | 151.76 |
| Previous Close | 150.05 |
| Day's Range | 149.92 - 152.08 |
| 52-Week Range | 101.00 - 159.42 |
| Beta | 0.92 |
| Analysts | Hold |
| Price Target | 156.75 (+4.45%) |
| Earnings Date | May 5, 2026 |
About DVA
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In... [Read more]
Financial Performance
In 2025, DaVita's revenue was $13.64 billion, an increase of 6.46% compared to the previous year's $12.82 billion. Earnings were $746.80 million, a decrease of -20.24%.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for DVA stock is "Hold." The 12-month stock price target is $156.75, which is an increase of 4.45% from the latest price.
News
Honeywell Announces Board of Directors for Honeywell Aerospace
Directors bring compelling mix of aerospace and defense expertise, leadership experience, and financial and capital markets backgrounds Honeywell spin-off of Honeywell Aerospace expected to be complet...
DaVita Inc. Schedules 1st Quarter 2026 Investor Conference Call
DENVER, April 20, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Tuesday, May 5, 2026, at 5:00 p.m. E...
DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement
Disclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy an...
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global dev...
DaVita Transcript: TD Cowen 46th Annual Health Care Conference
2026 OI growth is projected above the low end of long-term targets, driven by U.S. dialysis, international, and IKC segments. Margin maintenance, cost controls, and IT investments are key, while APTC expiration and clinical programs will shape future mix and volume. Double-digit EPS growth and disciplined capital deployment remain priorities.
DaVita Inc. to Participate in TD Cowen's 46th Annual Health Care Conference
DENVER, Feb. 24, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will par...
DaVita Stock Rallies On Profit Beat, Confident 2026 View
DaVita Inc. (NYSE: DVA) stock surged on Tuesday after the company reported upbeat fourth-quarter earnings and fiscal 2026 guidance.
TER Quarterly Sales Top $1B, DVA & PEP Beat Earnings
The AI trade is helping Teradyne (TER), with Diane King Hall pointing to the company's latest earnings as a signal of forward strength. Outside of tech, she notes DaVita's (DVA) earnings beat and guid...
DaVita forecasts 2026 profit above estimates on steady dialysis service demand; shares jump
DaVita projected annual profit above estimates on Monday after reporting better-than-expected fourth-quarter results on steady demand for its kidney dialysis services, sending its shares up 13% in aft...
DaVita Earnings Call Transcript: Q4 2025
Fourth quarter and full-year 2025 results met expectations, with adjusted operating income of $2.094 billion and first profitable year in IKC. 2026 guidance calls for 3.2% OI growth and 33% EPS growth, supported by clinical initiatives and capital discipline.
DaVita Inc. 4th Quarter 2025 Results
DENVER, Feb. 2, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter and year ended December 31, 2025. "Our strong platform delivered once again in 20...
DaVita Inc. Schedules 4th Quarter 2025 Investor Conference Call
DENVER, Jan. 21, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Monday, February 2, 2026 at 5:00 p.m...
DaVita Names New Leaders to Accelerate Care Transformation
Appointments of Chief People Officer and Chief Strategy Officer underscore commitment to innovation and people-first approach DENVER , Dec. 11, 2025 /PRNewswire/ -- DaVita, a leading provider of kidne...
DaVita Transcript: Wolfe Research Healthcare Conference 2025
Volume and revenue per treatment were challenged by flu and a cyber incident, but guidance was maintained. Mortality and mistreatment rates remain elevated, with future growth hinging on operational improvements and mortality reduction. Capital allocation is focused on share buybacks and disciplined M&A.
DaVita Inc. to Participate in Fireside Chat with Wolfe Research
DENVER , Nov. 14, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, will participate in a fireside chat at the Wolfe Research Healthcare Con...
DaVita Marks 25 Years of Innovation with Breakthrough Kidney Care Research at ASN Kidney Week 2025
Six new studies from DaVita Clinical Research spotlight improved outcomes with GLP-1 use, advancements in treatments, transplant access and end-of-life care DENVER and HOUSTON , Nov. 4, 2025 /PRNewsw...
DaVita misses quarterly profit estimates on rising costs, lower volumes
DaVita missed Wall Street estimates for third-quarter profit on Wednesday, as the kidney dialysis provider grappled with rising patient care costs and declining treatment volumes.
DaVita Earnings Call Transcript: Q3 2025
Q3 results met expectations with $517M adjusted operating income and $2.51 EPS, despite a 1.5% volume decline due to discrete events. Full-year guidance was reaffirmed, with 2026 outlook hinging on volume recovery, payer mix, and policy changes.
DaVita Inc. 3rd Quarter 2025 Results
DENVER , Oct. 29, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2025. "Our third quarter performance was in line with our e...
DaVita Leads the Way in Evaluating Middle Molecule Clearance with Two New Initiatives
New U.S. data will offer first-of-its-kind evidence in patients with kidney failure DENVER , Oct. 20, 2025 /PRNewswire/ -- DaVita today announced the launch of two groundbreaking initiatives aimed to...
DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call
DENVER , Oct. 13, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Wednesday, October 29, 2025, at 5:00...
DaVita Honors 25 Years of Clinical Advancement in Chronic Disease Care
Largest kidney care research arm advances science to inform care delivery DENVER , Aug. 27, 2025 /PRNewswire/ -- As part of its 25th-anniversary celebration, DaVita, a leading provider of comprehensiv...
Ransomware attack at dialysis firm DaVita affects 2.7 million people, US health dept website shows
A ransomware attack that encrypted certain elements of dialysis firm DaVita's network affected 2.7 million people, the U.S. health department's website showed on Thursday.
DaVita beats quarterly profit on steady demand for dialysis services
DaVita beat Wall Street estimates for second-quarter profit on Tuesday, driven by demand for its kidney dialysis services.